^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MSLN expression

    i
    Other names: MSLN, CAK1, MPF, Mesothelin
    Entrez ID:
    10232
    Related biomarkers:
    Expression
    Others
    1d
    Preclinical evaluation of 89Zr/177Lu-labeled amatuximab for theranostic application in pancreatic ductal adenocarcinoma. (PubMed, Int J Pharm)
    Furthermore, in vivo studies indicated that 177Lu-DOTA-amatuximab exhibited limited side effects. The development of 89Zr/177Lu-labeled amatuximab may provide novel insights into the formulation of precision diagnostic and therapeutic strategies for MSLN- overexpressing tumors, including PDAC.
    Preclinical • Journal • IO biomarker
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN overexpression
    |
    amatuximab (MORAb-009)
    21d
    Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC) (clinicaltrials.gov)
    P=N/A, N=371, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Oct 2024 | Trial primary completion date: Sep 2025 --> Oct 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    22d
    Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=15 --> 9
    Enrollment closed • Enrollment change
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin)
    |
    MSLN expression • HLA-A*02
    |
    cyclophosphamide • bendamustine • fludarabine IV • FH-TCR-Tᴍsʟɴ
    28d
    Microenvironmental alkalization promotes the therapeutic effects of MSLN-CAR-T cells. (PubMed, J Immunother Cancer)
    Moreover, mechanistic exploration revealed that the attenuation of autophagy-lysosome function caused by microenvironmental alkalization inhibited the degradation of MSLN. Hence, alkalization of the microenvironment improves the consistency and high expression of the target antigen MSLN and constitutes a routine method for treating diverse solid cancers via MSLN-CAR-T cells.
    Journal • CAR T-Cell Therapy • IO biomarker
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    1m
    Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    MSLN expression
    |
    Keytruda (pembrolizumab) • anetumab ravtansine (BAY 94-9343)
    1m
    Soluble Mesothelin-Related Peptide as a Prognosticator in Pleural Mesothelioma Patients Receiving Checkpoint Immunotherapy. (PubMed, J Thorac Cardiovasc Surg)
    SMRP is a promising serum biomarker for predicting survival in MPM patients treated with ICT and warrants prospective investigation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    1m
    EVEREST-2: a seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity (SITC 2024)
    a May occur at any point in disease course. CRC, colorectal cancer; D, day; MESO, mesothelioma; NSCLC, non-small cell lung cancer; OVCA, ovarian cancer; PANC, pancreatic cancer; PCLD, preconditioning lymphodepletionDownload figure Open in new tab Download powerpoint Abstract 627 Figure 3 EVEREST-2 phase 1 dose escalation study design
    Clinical • P1/2 data • CAR T-Cell Therapy • IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin)
    |
    MSLN expression • HLA-A*02
    |
    Tempus HLA-LOH assay
    |
    Ovarian cancer CAR-T therapy
    2ms
    Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC) (clinicaltrials.gov)
    P=N/A, N=371, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    2ms
    Characterization of mesothelin gene expression in dogs and overexpression in canine mesotheliomas. (PubMed, Front Vet Sci)
    Canine mesothelin exhibits molecular and biological characteristics akin to human mesothelin. It could serve as a vital biomarker for diagnosing canine mesotheliomas, applicable to both tissue- and effusion-based samples.
    Journal
    |
    MSLN (Mesothelin) • FURIN (Furin, Paired Basic Amino Acid Cleaving Enzyme)
    |
    MSLN expression • MSLN overexpression
    2ms
    A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers (clinicaltrials.gov)
    P1, N=70, Recruiting, Light Chain Bioscience - Novimmune SA | N=40 --> 70 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Jun 2025 --> May 2026
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    Keytruda (pembrolizumab) • paclitaxel • NI-1801
    2ms
    Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells. (PubMed, BMC Med)
    These findings serve as a proof-of-concept for using multiple immunogenic peptides as a novel therapeutic approach in TNBC patients.
    Journal
    |
    CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • IFNG (Interferon, gamma) • MSLN (Mesothelin) • FASLG (Fas ligand) • NCL (Nucleolin)
    |
    MSLN expression • HLA-A*02
    7ms
    Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers. (PubMed, Front Oncol)
    Further testing of tofacitinib to prevent ADA formation is recommended in applicable non-malignant disease settings. https://www.clinicaltrials.gov/study/NCT04034238.
    Journal • Metastases
    |
    MSLN (Mesothelin) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    MSLN expression
    |
    tofacitinib • LMB-100
    7ms
    A bispecific antibody that targets the membrane-proximal region of mesothelin and retains high anticancer activity in the presence of shed mesothelin. (PubMed, Mol Cancer Ther)
    Our findings indicate that by targeting the protease-sensitive region of MSLN, BsAb 5 has high MSLN-specific anticancer activity that is not inhibited by shed MSLN. BsAb 5 may be a promising immunotherapy candidate for MSLN-expressing cancers.
    Journal
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    7ms
    Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov)
    P1/2, N=113, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • MSLN (Mesothelin)
    |
    MSLN expression
    |
    Keytruda (pembrolizumab) • cyclophosphamide • iCasp9M28z T cell infusion
    7ms
    MSLN induced EMT, cancer stem cell traits and chemotherapy resistance of pancreatic cancer cells. (PubMed, Heliyon)
    Sensitivity of tumor cells to gemcitabine was evaluated...We concluded that MSLN could induce chemoresistance by enhancing migration, invasion, EMT and cancer stem cell traits of pancreatic cancer cells. Targeting MSLN could represent a promising therapeutic strategy for reversing EMT and chemoresistance in pancreatic cancer cells.
    Journal • Cancer stem
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN overexpression
    |
    gemcitabine
    7ms
    Selection, engineering, and in vivo testing of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin. (PubMed, PLoS One)
    HiTs can be isolated from fully human TCR-displaying phage libraries against cell surface-expressed antigens. HiTs are able to fully activate primary T cells both in vivo and in vitro. HiTs may enable the efficacy seen with pHLA-targeting TCRs in solid tumors to be translated to cell surface antigens.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • MSLN (Mesothelin) • CD4 (CD4 Molecule)
    |
    MSLN expression
    7ms
    Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET. (PubMed, J Exp Clin Cancer Res)
    Our results demonstrate that MSLN plays a critical role in BM of NSCLC by modulating the JNK/MET signaling network and thus, provides a potential novel therapeutic target for preventing BM in NSCLC patients.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • MSLN (Mesothelin) • MAPK8 (Mitogen-activated protein kinase 8)
    |
    MET expression • MSLN expression
    |
    Xalkori (crizotinib) • Tabrecta (capmatinib)
    8ms
    LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=6, Terminated, National Cancer Institute (NCI) | Trial completion date: Mar 2024 --> Dec 2023 | Active, not recruiting --> Terminated; Study was terminated due to slow accrual.
    Trial completion date • Trial termination
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MSLN (Mesothelin) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    KRAS mutation • EGFR mutation • MSLN expression
    |
    Keytruda (pembrolizumab) • LMB-100
    9ms
    Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (clinicaltrials.gov)
    P1/2, N=36, Active, not recruiting, TCR2 Therapeutics | Recruiting --> Active, not recruiting | N=175 --> 36 | Trial completion date: Apr 2026 --> Nov 2028 | Trial primary completion date: Jul 2024 --> Nov 2028
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV
    9ms
    A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, TCR2 Therapeutics | Trial completion date: Dec 2027 --> Oct 2028 | Trial primary completion date: Nov 2023 --> Oct 2028
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • TC-510
    9ms
    Enhanced Expression of Glycolytic Enzymes and Succinate Dehydrogenase Complex Flavoprotein Subunit A by Mesothelin Promotes Glycolysis and Mitochondrial Respiration in Myeloblasts of Acute Myeloid Leukemia. (PubMed, Int J Mol Sci)
    The collective results demonstrate that mesothelin induces metabolic changes in leukemia cells, facilitating the acquisition of a rapid supply of ATP for proliferation in AML. Therefore, the targeting of mesothelin presents a potentially promising approach to mitigating the progression of AML through the inhibition of glycolysis and mitochondrial respiration in myeloid cells.
    Journal
    |
    MSLN (Mesothelin) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A)
    |
    MSLN expression • MSLN positive
    9ms
    Recent Developments in Nanotechnology and Immunotherapy for the Diagnosis and Treatment of Pancreatic Cancer. (PubMed, Curr Pharm Biotechnol)
    Recent advancements in checkpoint inhibitors, adoptive T cell therapies, and cancer vaccines have shown potential in overcoming the immune evasion mechanisms of pancreatic cancer cells. Combining these immunotherapeutic approaches with nanocarriers holds great promise in enhancing the antitumor response and improving patient survival.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • MSLN (Mesothelin) • MUC1 (Mucin 1)
    |
    MSLN expression
    9ms
    NCI10208: Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1, N=74, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Combination therapy • Tumor mutational burden • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • ABP 206 (nivolumab biosimilar)
    10ms
    EVEREST-2: A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (clinicaltrials.gov)
    P1/2, N=230, Recruiting, A2 Biotherapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin)
    |
    MSLN expression • HLA-A*02
    10ms
    Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies. (PubMed, Int J Nanomedicine)
    A 3D cell culture model based on MSLN-expressing multicellular tumor spheroids reveals NA penetration in the first superficial layers. Altogether, these results open the path to novel anticancer strategies based on MSLN-activated internalization of NA incorporating drugs to promote specific accumulation of active treatments in tumors.
    Journal
    |
    MSLN (Mesothelin) • DNM3 (Dynamin 3)
    |
    MSLN expression
    10ms
    Clinical Significance Of Mesothelin Expression And Its Correlation With HER2 In Gynecologic Carcinosarcoma (ESGO 2024)
    In this study, MSLN expression is widely observed in UCS. Moreover, high-MSLN expression is a favorable prognostic factor for UCS, which could be a promising therapeutic target, regardless of HER2 expression. This study was published in the Journal of Gynecologic Oncology.
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSLN (Mesothelin)
    |
    HER-2 negative • HER-2 expression • MSLN expression • MSLN positive
    |
    VENTANA MSLN (SP74) ASSAY
    10ms
    Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=15, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Sep 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin)
    |
    MSLN expression • HLA-A*02
    |
    cyclophosphamide • bendamustine • fludarabine IV • FH-TCR-Tᴍsʟɴ
    11ms
    EVEREST-2: A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (clinicaltrials.gov)
    P1/2, N=230, Not yet recruiting, A2 Biotherapeutics Inc.
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin)
    |
    MSLN expression • HLA-A*02
    11ms
    A Study of TAK-103 in Adult With Solid Tumors (clinicaltrials.gov)
    P1, N=2, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting | N=21 --> 2
    Enrollment closed • Enrollment change • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    NIB103
    11ms
    Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2027 --> Dec 2024 | Trial primary completion date: Dec 2026 --> Dec 2024
    Trial completion date • Trial primary completion date • Surgery
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    LMB-100
    11ms
    Killing effect of anti-MSLN-iCAR-NK cells derived from induced pluripotent stem cells on ovarian epithelial cancer cells (PubMed, Zhonghua Fu Chan Ke Za Zhi)
    (3) ELISA analysis revealed that the expression levels of IFN-γ, TNF-α, GZMB, PRF1, IL-6, and IL-10 in ovarian cancer cells of the anti-MSLN-iCAR-NK cell group were significantly higher than those in the NK cell group and the control group (all P<0.05). The anti-MSLN-iCAR-NK cells exhibit a strong killing ability against ovarian cancer cells, indicating their potential as a novel immunotherapy approach for ovarian cancer.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • MSLN (Mesothelin) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • GZMB (Granzyme B) • PRF1 (Perforin 1)
    |
    MSLN expression • IFNG expression
    11ms
    A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, TCR2 Therapeutics | Recruiting --> Active, not recruiting | N=140 --> 6 | Trial primary completion date: Jun 2025 --> Nov 2023
    Enrollment closed • Enrollment change • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • TC-510
    11ms
    A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=81, Recruiting, RemeGen Co., Ltd. | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    misitatug blivedotin (RC88)
    11ms
    M9657 is a bispecific tumor-targeted anti-CD137 agonist that induces MSLN-dependent antitumor immunity without liver inflammation. (PubMed, Cancer Immunol Res)
    Development of the first-generation CD137-agonist monotherapies utomilumab and urelumab was unsuccessful due to low antitumor efficacy mediated by the epitope recognized on CD137 or hepatotoxicity mediated by FcγR ligand-dependent CD137 activation, respectively. Compared with 3H3, a murine surrogate of urelumab, FS122m and chimeric M9657 displayed significantly lower on-target/off-tumor toxicity. Taken together, M9657 exhibits a promising profile for development as a tumor-targeting immune agonist with potent anticancer activity without systemic immune activation and associated hepatotoxicity.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • MSLN (Mesothelin)
    |
    MSLN expression
    |
    utomilumab (PF-05082566) • urelumab (BMS-663513)
    11ms
    Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor. (PubMed, Cancer Immunol Immunother)
    T cells expressing a mesothelin (MSLN)-specific T cell receptor fusion construct (TRuC), called TC-210, have demonstrated robust antitumor activity in preclinical models of mesothelioma, ovarian cancer, and lung cancer. These data demonstrate that integration of a PD1-CD28 CSR into TRuC-T cells improves effector function, resistance to exhaustion, and prolongs persistence. Based on these findings, TC-510 is currently being evaluated in patients with MSLN-expressing solid tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • MSLN (Mesothelin) • CD28 (CD28 Molecule)
    |
    PD-L1 expression • MSLN expression • PD-1 expression
    |
    gavocabtagene autoleucel (TC-210) • TC-510
    12ms
    Assessment of Novel Mesothelin-Specific Human Antibody Domain VH-Fc Fusion Proteins-Based PET Agents. (PubMed, ACS Omega)
    Furthermore, PET imaging allowed us to compare the pharmacokinetics of epitope-specific VH domain-based PET tracers. Overall, these data are encouraging for the incorporation of PET imaging to assess modified VH domain structures to develop novel anti-MSLN VH domain-based therapeutics in MSLN-positive cancers as well as their companion PET imaging agents.
    Journal
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    1year
    Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression. (PubMed, J Gynecol Oncol)
    MSLN expression is widely observed in gynecological carcinosarcomas. Moreover, high-MSLN expression is a favorable prognostic factor for UCS. MSLN could be a promising therapeutic target for UCS, even in the era of anti-HER2 therapy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSLN (Mesothelin)
    |
    HER-2 negative • HER-2 expression • MSLN expression • MSLN positive
    |
    VENTANA MSLN (SP74) ASSAY
    1year
    Development of Novel Lipid Nanoparticles and Virus-like Particles for In Vivo Engineering of Immune Cells for Targeted Cancer Therapy (ASH 2023)
    We are currently doing similar in vivo studies to test the efficiency of ab-LNPs. Next, we will translate these promising results to an in vivo ovarian cancer mice model to engineer endogenous immune cells to directly express CARs, as new strategy to overcome the current problems of cell and gene therapies, starting by develop an effective and safety therapy for treatment of diverse refractory malignancies.
    Preclinical • Immune cell
    |
    CD14 (CD14 Molecule)
    |
    MSLN expression
    1year
    Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma. (PubMed, Front Immunol)
    In the exploratory cohort, low mesothelin and high COL1A1 and COL5A1 expression were associated with poor overall survival. Tumor mesothelin expression associated with the TME immune landscape predicts the risk of death for patients with MPM and could be a new target for immunotherapy in MPM.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • MSLN (Mesothelin) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • COL1A1 (Collagen Type I Alpha 1 Chain) • COL5A1 (Collagen Type V Alpha 1 Chain)
    |
    MSLN expression
    1year
    Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer. (PubMed, J Cancer Res Clin Oncol)
    Our results suggest that irinotecan can enhance the antitumor activity of MSLN-targeted CAR T cells, and offer a promising combination therapy strategy for MSLN-positive solid tumors.
    Journal
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    irinotecan
    1year
    Biology of Mesothelin and Clinical Implications: A Review of Existing Literature. (PubMed, World J Oncol)
    Finally, the unified mechanism by which MSLN acts as a protein that conveys tumor aggressiveness remains elusive. What is clear is that there is much yet to be discovered in this realm and doing so may have large implications for treatment of otherwise lethal malignancies.
    Review • Journal
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    1year
    CHOLESTASIS-ACTIVATED PORTAL FIBROBLASTS REGULATE HEPATOCYTE SENESCENCE AND HEPATOCARCINOGENESIS IN AGED Mdr2 KO MICE (AASLD 2023)
    Here we report a novel function of portal fibroblasts as drivers of cholestatic fibrosis, ductular reaction, inflammation, hepatocyte senescence, and HCC in aged mice, demonstrating the key role of the tumor microenvironment.
    Preclinical • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • MSLN (Mesothelin) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • MUC16 (Mucin 16, Cell Surface Associated) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD34 (CD34 molecule) • GPC3 (Glypican 3) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • BCL2L2 (BCL2 Like 2) • CD68 (CD68 Molecule) • SOX9 (SRY-Box Transcription Factor 9) • COL1A1 (Collagen Type I Alpha 1 Chain) • THY1 (Thy-1 membrane glycoprotein) • ABCB4 (ATP Binding Cassette Subfamily B Member 4) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • IL1B (Interleukin 1, beta)
    |
    MSLN expression • MUC16 expression